DXCM Technical Analysis
As of date:5/12/2022
DXCM stock price:311.52
DXCM 50 DMA:444.25
DXCM 200 DMA:502.58
DXCM MACD (200-50):58.33
DXCM RSI:8.21
Extremely
Overbought
Overbought/Oversold RSI Range
RSI Indicator (Relative Strength Index)8.21
Extremely
Oversold

Also see:
DXCM Market Cap History
DXCM Shares Outstanding History
DXCM YTD Return

Try ChartSweeps today
Quotes delayed 20 minutes

Email EnvelopeFree DXCM Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts

Ingredion Breaks Above 200-Day Moving Average - Bullish for INGR
1 hour, 58 minutes ago


Ryder System Shares Cross Above 200 DMA
2 hours, 4 minutes ago


Centerra Gold Crosses Above Key Moving Average Level
2 hours, 9 minutes ago


Bullish Two Hundred Day Moving Average Cross
2 hours, 9 minutes ago


Orezone Gold Corp Breaks Above 200-Day Moving Average
2 hours, 9 minutes ago


Intercure (INCR) Shares Cross Above 200 DMA
6 hours, 14 minutes ago


PCVX Makes Bullish Cross Above Critical Moving Average
6 hours, 17 minutes ago


Bullish Two Hundred Day Moving Average Cross - GTLS
6 hours, 18 minutes ago


Safety Insurance Group (SAFT) Shares Cross Below 200 DMA
6 hours, 18 minutes ago


Monster Beverage Corp (MNST) Shares Cross Above 200 DMA
6 hours, 18 minutes ago


SunOpta Inc Breaks Above 200-Day Moving Average - Bullish for STKL
6 hours, 35 minutes ago


IEP Makes Bullish Cross Above Critical Moving Average
6 hours, 36 minutes ago


Social Capital Hedosop Breaks Above 200-Day Moving Average - Bullish for IPOF
6 hours, 36 minutes ago


BIP Makes Bullish Cross Above Critical Moving Average
6 hours, 52 minutes ago


OI Crosses Above Key Moving Average Level
6 hours, 57 minutes ago


More Technical Analysis News

DXCM Technical AnalysisDXCM RSI
DexCom is a medical device company primarily focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems. Co.'s product candidates include Dexcom G7®, which is designed with the goal of carrying forward many of the same features as Co.'s G6 CGM system and adding several new or improved features. Co.'s products include: DexCom G6® integrated Continuous Glucose Monitoring System (G6), which is a type of CGM system to be used as part of an integrated system with other medical devices and electronic interfaces; and DexCom Share®, which transmit glucose information to the cloud and then to apps on the mobile devices of up to five designated recipients.

When researching a stock like DexCom, many investors are the most familiar with Fundamental Analysis — looking at a company's balance sheet, earnings, revenues, and what's happening in that company's underlying business. Investors who use Fundamental Analysis to identify good stocks to buy or sell can also benefit from DXCM Technical Analysis to help find a good entry or exit point. Technical Analysis is blind to the fundamentals and looks only at the trading data for DXCM stock — the real life supply and demand for the stock over time — and examines that data in different ways.
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks

10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
DXCM DMADXCM MACD
Video: Technical Analysis


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
DexCom (DXCM) is categorized under the Healthcare sector; to help you further research Technical Analysis, below are some other companies in the same sector:

EW Technical Analysis
GILD Technical Analysis
HCA Technical Analysis
HOLX Technical Analysis
HSIC Technical Analysis
IDXX Technical Analysis
ILMN Technical Analysis
INCY Technical Analysis
IQV Technical Analysis
ISRG Technical Analysis
More Healthcare companies »

 

DXCM Technical Analysis | www.TechnicalAnalysisChannel.com | Copyright © 2019 - 2022, All Rights Reserved

Nothing in TechnicalAnalysisChannel.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.